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IL-28 (IFN-l) cytokines exhibit potent antiviral and antitumor function but their
full spectrum of activities remains largely unknown. Recently, IL-28 cytokine
family members were found to be profoundly down-regulated in allergic asthma.
We now reveal a novel role of IL-28 cytokines in inducing type 1 immunity and
protection from allergic airway disease. Treatment of wild-type mice with
recombinant or adenovirally expressed IL-28A ameliorated allergic airway dis-
ease, suppressed Th2 and Th17 responses and induced IFN-g. Moreover, abroga-
tion of endogenous IL-28 cytokine function in IL-28Ra/ mice exacerbated
allergic airway inflammation by augmenting Th2 and Th17 responses, and IgE
levels. Central to IL-28A immunoregulatory activity was its capacity to modulate
lung CD11cþ dendritic cell (DC) function to down-regulate OX40L, up-regulate IL-
12p70 and promote Th1 differentiation. Consistently, IL-28A-mediated protec-
tion was absent in IFN-g/ mice or after IL-12 neutralization and could be
adoptively transferred by IL-28A-treated CD11cþ cells. These data demonstrate a
critical role of IL-28 cytokines in controlling T cell responses in vivo through the
modulation of lung CD11cþ DC function in experimental allergic asthma.
INTRODUCTION
Allergic asthma is due to the failure of the immune system to
develop tolerance to otherwise innocuous environmental
aeroallergens (Holgate & Polosa, 2008). As a result, inap-
propriate Th2-mediated immune responses are induced that
orchestrate the asthmatic response by promoting the produc-
tion of IgE, the infiltration of lymphocytes and eosinophils, and
the induction of airway inflammation and hyper-responsive-
ness (Umetsu & DeKruyff, 2006). Aeroallergen-directed Th17
responses can further contribute to this process by triggering
the infiltration of neutrophils and the hyper-secretion of mucus
(Holgate & Polosa, 2008). To prevent this from happening, the
host employs a multitude of often complementary regulatory
mechanisms that include the generation of Th1-specific
immune responses that cross-regulate Th2 responses to
allergen and/or the induction of regulatory T cell responses.
The rate-limiting step in the generation of Th2-mediated
allergic responses in the lung, and the induction of counter-
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regulatory Th1 or Treg responses, is the presentation of
allergen by local DCs (van Rijt et al, 2005). This is influenced
by the lung microenvironment and the presence of allergic or
infectious insults that trigger the expression of key inflamma-
tory cytokines such as thymic stromal lymphopoietin (TSLP)
and IL-12 that modulate DC function and promote Th2 or Th1
cell differentiation, respectively. Still, the majority of factors
responsible for controlling DC-mediated T helper cell polar-
ization, especially in the context of allergic disease, remain
incompletely understood.
Recently, a new family of cytokines known as interleukins-
28/29, l-interferons or type III interferons (IFN) was
discovered. IL-28/29 cytokines represent an interesting
evolutionary link between type I IFNs and the IL-10 family
(Kotenko et al, 2003; Sheppard et al, 2003; Siren et al, 2005).
They consist of three members in humans, denoted IL-28A
(IFN-l2), IL-28B (IFN-l3), and IL-29 (IFN-l1), and two
members in mice (IL-28A and IL-28B) (Lasfar et al, 2006),
all of which signal through a heterodimeric receptor consisting
of IL-28Ra (IFN-lR1 or CRF2-12) responsible for ligand
specificity, and IL-10Rb (IL-10R2 or CRF2-4) shared with all
other IL-10 family members. Although IL-10Rb is ubiquitously
expressed, IL-28Ra expression is restricted to cells of epithelial
derivation including hepatocytes and myeloid lineage cells
such as dendritic cells (DCs) and macrophages (Doyle et al,
2006; Mennechet & Uze, 2006).
IL-28 cytokine family members are produced by various cells
including antigen presenting cells upon viral infection or Toll
like receptor ligation (Doyle et al, 2006; Lauterbach et al, 2010;
Siebler et al, 2007; Siren et al, 2005). It is now well established
that IL-28 cytokines exhibit potent antiviral and anti-cancer
activity. They inhibit viral replication (Robek et al, 2005), they
up-regulate cytotoxic responses to virally infected cells (Ank et
al, 2008) and they reduce tumour growth andmetastases inmice
(Numasaki et al, 2007). More recently, additional activities of IL-
28 cytokine family members in the immune system have been
suggested. For instance, IL-29-treated DCs induce proliferation
of FoxP3-expressing regulatory T cells in vitro (Mennechet &
Uze, 2006), whereas addition of IL-29 to human PBMC or T cell
cultures in vitro inhibits the production of IL-5 and IL-13 (Dai et
al, 2009; Jordan et al, 2007; Srinivas et al, 2008). Moreover,
transgenic expression of IL-28A in vivo promotes the induction
of Th1 over Th2 responses and the severity of ConA-induced
liver injury (Siebler et al, 2007).
In humans, a strong link between low expression of IL-28
cytokines and severity of allergic asthma and allergic asthma
exacerbations has been described. Asthmatic patients exhibit
deficient induction of IL-28 and IL-29 in response to rhinovirus
infection, and deficient IL-28/29 expression correlates with the
severity of rhinovirus-induced asthma exacerbations and virus
load in experimentally infected human volunteers (Contoli et al,
2006). Moreover, in the absence of detectable viral infection
asthmatic patients with active disease still exhibit an inverse
correlation between IL-28 and IL-29mRNA levels and severity of
the allergic response in the airways (Bullens et al, 2008). This
raises the possibility that in addition to their role in antiviral
immunity IL-28 cytokines may also modulate adaptive immune
responses that underlie the pathogenesis of asthma. Here, we
demonstrate that IL-28A promotes Th1 cell differentiation in
vivo and suppresses Th2-mediated responses in the airways, and
we identify IL-28 cytokines as new immunotherapeutic agents
for the treatment of allergic airway disease.
RESULTS
Overexpression of IL-28A in the lung inhibits Th2 and Th17
responses and suppresses allergic airway disease
To explore the role of IL-28 cytokines in allergic airway disease,
we used an established mouse model of allergen sensitization
and challenge (Fig 1A). We first investigated the expression of
IL-28A and IL-28B (97% identical in amino acid sequence) in the
bronchoalveolar lavage fluid (BALF) during the development of
allergic airway inflammation and found that, similarly to human
patients, IL-28 cytokines were expressed at only low levels
(Fig 1B). To up-regulate IL-28 levels and examine whether this
has functional consequences in disease development, we
constructed a recombinant replication-deficient adenovirus
expressing IL-28A under control of the CMV promoter
(AdIL-28) and applied it to the lung. This resulted in high
levels of IL-28A production in the BALF of treated mice (Fig 1B),
which profoundly impacted on allergic airway disease. We
found that AdIL-28 but not Ad0 or vehicle control treatments
significantly reduced eosinophil, neutrophil and lymphocyte
cell numbers in the BALF (Fig 1C–D) and leukocyte infiltration
in the perivascular and peribronchial areas of the lung (Fig 1E).
This was accompanied by significantly decreased goblet cell
metaplasia and hyper-secretion of airway epithelial mucus in
the lung of AdIL-28-treated mice compared to controls (Fig 1F).
Notably, effector Th2 and Th17 responses to OVA were also
suppressed as demonstrated by the inhibition of IL-5, IL-10, IL-
13 and IL-17 in the lung-draining mediastinal lymph nodes
(MLNs), whereas the Th1 cytokine IFN-g was up-regulated
(Fig 1G). In contrast, IL-4 was not detectable in this assay (data
not shown). Finally, protection from airway hyper-responsive-
ness (AHR) measured as metacholine-induced increases in total
lung resistance was observed in mice treated with AdIL-28,
whereas mock adenovirus (Ad0) or vehicle administration
(PBS) had no effect (Fig 1H). Collectively, these findings
demonstrate that high IL-28A levels in the lung effectively
suppress the development of Th2 and Th17 cell mediated
inflammatory responses and Th2-mediated allergic airway
disease.
Intranasal administration of recombinant IL-28A effectively
treats allergic airway disease in mice
Subsequently, we examined whether recombinant IL-28A (IL-
28A) administered intranasally during OVA challenge (Fig 2A)
would also be capable of suppressing Th2-mediated allergic
airway disease and thus whether it could be therapeutically
useful. Indeed, we found that IL-28A treatment effectively
suppressed the number of eosinophils and neutrophils in the
BALF (Fig 2B) although it had no effect on the number of
lymphocytes (Fig 2C). IL-28A treatment also inhibited the
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infiltration of leukocytes in the lung (Fig 2D) and led to the
reduction of goblet cell metaplasia (Fig 2E). Notably, IL-28A-
mediated suppression of disease severity was accompanied by
a significant inhibition of IL-5, IL-13 and IL-17 in lung-draining
MLNs and a marked up-regulation of IFN-g (Fig 2F). Similar
inhibition of Th2 and Th17 responses was also observed in
purified lung CD4þ T cells from IL-28A treated mice
(Supporting Information Fig S1A–B). Finally, IL-28A treatment
ameliorated lung function by reducing AHR in response to
increasing doses of MCh (Fig 2G). These data support a potent
therapeutic effect of recombinant IL-28A treatment in allergic
airway disease.
IL-28RaS/S mice exhibit augmented Th2 and Th17 responses
and exacerbated allergic airway inflammation
To explore the role of endogenous IL-28 cytokine production in
allergic airway disease, we took advantage of mice in which the
IL-28RA gene encoding the alpha chain of the IL-28 receptor
complex has been inactivated by homologous recombination
(Ank et al, 2008). Using the OVA model of allergic airway
inflammation (Fig 1A), we found that OVA-sensitized and
-challenged IL-28Ra/ mice exhibited a significant increase in
eosinophilic cell infiltration in the BALF as compared to wild-
type controls (Fig 3A, left panel). Although eosinophils
constituted the main infiltrating cell population in the lung,
Research Article
IL-28 promotes Th1 skewing and suppresses asthma
10
15
op
hi
ls
x1
05
/m
l
6
8
10
op
hi
ls
x1
04
/ m
l
100
1000
10000
pg
/m
l)
BA C
PBS, Ad0, AdIL-28 
treatment i.t.
Time (d)
**
***
*
*
***
***
P
B
S
A
d0
A
dI
L-
28
P
B
S
A
d0
A
dI
L-
28
0
5
E
os
in
o
in
 B
A
LF
 x
P
B
S
A
d0
A
dI
L-
28
P
B
S
A
d0
A
dI
L-
28
0
2
4
N
eu
tro
in
 B
A
LF
 x
PB
S/
PB
S
O
V
A
/O
V
A
PB
S
Ad
0
Ad
IL
-2
81
10
IL
-2
8 
(
0 7 14 15 16 17
Sensitization
OVA/Alum i.p.
Challenge
OVA aerosol
AHR, BAL, Tissue 
collection, assays
13
PBS/PBS OVA/OVA PBS/PBS OVA/OVA
**
10
15
cy
te
s
10
4 /
m
l
P O
15
20
pi
xe
ls
/µ
m
)
6
8
al
 s
co
re
D F
OVA/OVA
E ***
***
PBS
***
***
*
**
PBS                          Ad0                       AdIL-28
P
BS A
d0
A
dI
L-
28
P
BS A
d0
A
dI
L-
28
0
5
Ly
m
ph
oc
in
 B
AL
F 
x1
PBSAd0 AdIL-28
0
5
10
PA
S 
Sc
or
e 
(p
PBSAd0 AdIL-28
0
2
4
H
is
to
lo
gi
ca
OVA/OVA
Ad0
AdIL-28A
OVA/OVA
PBS
Ad0
AdIL-28
PBS
Ad0
AdIL-28
PBS
Ad0
AdIL-28
G
900
1100
1300
1500
PBS
Ad0se
lin
e)
OVA/OVA
H
***
*** ***
*** **
PBS
Ad0
AdIL-28
PBS
Ad0
AdIL-28
0 200 400 600 800
IL-5 (pg/ml)
0 2000 4000
IL-13 (pg/ml)
0 100 200 300 400 500
IL-17 (pg/ml)
BL 0 3,33 33,3 100 333
100
300
500
700
PBS/PBS
AdIL-28
MCh d [ / l]
R
L 
(%
 o
f b
as
***
***
*
*
**
**
**
0 500 1000 1500
IL-10 pg/ml
0 250 500 750 1000
IFNγ (pg/ml)
ose mg m
Figure 1. Adenoviral expression of IL-28A during allergen challenge suppresses the development of allergic airway disease.
A. Experimental protocol. C57BL/6 mice were subjected to vehicle (PBS), mock (Ad0) or IL-28A expressing adenovirus (AdIL-28) treatment in the lung and then
challenged with aerosolized OVA (OVA/OVA) or PBS (PBS/PBS).
B. Total IL-28 levels in the BALF of lungs from PBS or OVA-sensitized and challenged mice in the presence of AdIL-28, Ad0 or PBS treatment. For the analysis of IL-
28 levels, BALF was concentrated 10X as detailed in Materials and Methods section. Results are expressed as mean values SEM of 4–8 mice per group from
two independent experiments.
C. BALF differential counts for eosinophils and neutrophils expressed as mean SEM of 10–14 mice per group from three independent experiments are shown.
D. BALF differential counts for lymphocytes expressed as mean SEM of 10–14 mice per group from three independent experiments are shown.
E. Histological assessment of lung inflammation in AdIL-28-treated mice. Hematoxylin and eosin stained lung sections and histological scoring expressed as
mean values SEM from 10 mice per group are shown.
F. Histological assessment of mucus secretion in AdIL-28-treatedmice. Periodic acid Schiff (PAS)-stained sections and morphometric analysis expressed as mean
values SEM from 10 mice per group are shown.
G. Effector T cell responses in MLNs of OVA sensitized and challenged mice. Cytokine levels in supernatants of OVA-stimulated MLN cultures expressed as mean
values SEM of five mice per group are shown. Data are representative of two independent experiments.
H. AHR measured as metacholine-induced increases in total lung resistance (RL) in mechanically ventilated mice. Data are expressed as mean values of
percentage increase from baseline of the total RL SEM of eight mice per group from two independent experiments. p< 0.05; p<0.01; p< 0.001.
350  2011 EMBO Molecular Medicine EMBO Mol Med 3, 348–361 www.embomolmed.org
an increase in neutrophils (Fig 3A, right panel) and a tendency
for increased lymphocytes (Fig 3B) was also observed in IL-
28Ra/ mice. This was further accompanied by significantly
enhanced inflammatory infiltrates in the lung (Fig 3C) and
goblet cell metaplasia in the airways (Fig 3D) of IL-28Ra/
mice. Notably, effector Th2 and Th17 cell responses against
OVAwere also increased in IL-28Ra/mice.MLN cells from IL-
28Ra/ mice exhibited significantly higher levels of IL-5, IL-13
and IL-17 than their wild-type counterparts whereas IFN-g levels
were very low, due to the strong Th2 skewing of this model, and
not affected (Fig 3E). Similar observations were also made when
CD4þ T cells from the lung of IL-28Ra/ mice were analysed
(Supporting Information Fig S2A–C). Although IL-4 was not
detectable in MLN cultures, it was readily produced in CD4þ T
cell cultures from the lung and significantly up-regulated in
IL-28Ra/ mice (Supporting Information Fig S2A). Finally,
IL-28Ra/ mice exhibited increased IgE levels in the serum
compared to wild-type controls (Fig 3F).
In contrast, AHR ofOVA-sensitized and challenged IL-28Ra/
mice was only marginally affected at saline and low MCh doses
but not thereafter (Fig 3G), suggesting the influence of
additional non-inflammatory parameters to this response.
Indeed, remodelling changes such as increased collagen
deposition around the bronchi were also observed in IL-
28Ra/ mice (Supporting Information Fig S2D). Taken
together, these data indicate that endogenously produced IL-
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Figure 2. Treatment with recombinant IL-28A suppresses Th2/Th17 cytokine production and ameliorates allergic airway disease.
A. Experimental protocol. BALB/c mice were challenged for three consecutive days with inhaled OVA in the absence (OVA/OVAþ PBS) or presence of recombinant
IL-28A (OVA/OVAþ IL-28A). Control mice were challenged with PBS (PBS/PBS).
B. BALF differential counts for eosinophils and neutrophils expressed as mean SEM of 3–4 mice per group. One representative of two independent experiments
is shown.
C. BALF differential counts for lymphocytes expressed as mean SEM of 3–4 mice per group. One representative of two independent experiments is shown.
D. Histological assessment of lung inflammation in IL-28A-treatedmice. Hematoxylin and eosin stained lung sections and histological scoring expressed as mean
values SEM from six mice per group are shown.
E. Histological assessment of mucus secretion in IL-28A-treated mice. PAS stained sections and morphometric analysis expressed as mean values SEM from six
mice per group are shown.
F. Effector T cell responses in MLNs of OVA sensitized and challenged mice. Cytokine levels are expressed as mean values SEM in supernatants of OVA-
stimulated MLN cultures of 10–12 mice per group from two independent experiments.
G. AHR measured as metacholine-induced increases in total lung resistance (RL) in anesthetized BALB/c mice. Data are expressed as mean values of percentage
increase from baseline of the total RL SEM of five mice per group. One representative of three independent experiments is shown. p<0.05; p< 0.01;
p<0.001.
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28 cytokines are involved in damping down allergic airway
inflammation and mucus hyper-secretion in mice.
IL-28 cytokines drive Th1 differentiation in vivo
Inhibition of effector Th2 responses and induction of IFN-g seem
to be central to IL-28A-mediated suppression of allergic airway
disease. To get insight into this process, we examined the ability
of IL-28 cytokines to modulate T helper cell differentiation
during a primary immune response in vivo. We found that
during primary immunization with OVA in alum, IL-28Ra/
mice developed markedly enhanced Th2 and Th17 responses to
OVA than their wild-type counterparts characterized by
increased production of IL-4, IL-5, IL-13 and IL-17 (Fig 4A).
At the same time, IL-28Ra/ mice exhibited impaired IFN-g
production in response to OVA (Fig 4B) or the immunodominant
CD4þ T cell specific OVA peptide OT-II (Fig 4C), suggesting that
endogenous IL-28 cytokines (IL-28A and/or IL-28B) are
critically involved in promoting CD4þ T cell differentiation to
a Th1 phenotype. IL-28-induced Th1 cell differentiation appears
to be a general aspect of the biology of IL-28 cytokines as mice
immunized with OVA emulsified in Complete Freud’s adjuvant
(OVA/CFA), a potent Th1-inducing adjuvant, also exhibited
reduced Th1 and enhanced Th2 responses to OVA (Supporting
Information Fig S3A–B). On the contrary, IL-28A overexpression
during primary immunization with OVA in alum exerted exactly
the opposite effect by increasing IFN-g and reducing IL-5, IL-13
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Figure 3. IL-28Ra-deficient mice develop increased Th2/Th17 responses and Th2/Th17-mediated allergic airway inflammation.
A. BALF differential counts of eosinophils and neutrophils expressed as mean SEM of 3–4 mice per group. One representative from three independent
experiments is shown.
B. BALF differential counts of lymphocytes expressed as mean SEM of 3–4 mice per group. One representative from three independent experiments is shown.
C. Histological assessment of lung inflammation in IL-28Raþ/þ and IL-28Ra/ mice. Hematoxylin and eosin stained lung sections and histological scoring
expressed as mean values SEM from 5 to 7 mice per group are shown.
D. Histological assessment of mucus secretion in IL-28Raþ/þ and IL-28Ra/ mice. PAS stained sections and morphometric analysis expressed as mean
values SEM from 5 to 7 mice per group are shown.
E. Effector T cell responses in MLNs of OVA sensitized and challenged mice. Cytokine levels in supernatants of OVA-stimulated MLN cultures expressed as mean
values SEM of seven mice per group from two independent experiments are shown.
F. Increased total IgE levels in the serum of IL-28Ra/ mice as compared to IL-28Raþ/þ littermates after OVA sensitization and challenge. Data represent mean
values SEM.
G. AHR measured as metacholine-induced increases of total lung resistance (RL) in mechanically ventilated IL-28Raþ/þ and IL-28Ra/ mice. Data are expressed
as mean values of percentage increase from baseline of the total RL SEM from 10 mice per group pooled from two independent experiments. p< 0.05;
p<0.01; p< 0.001.
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and IL-17 production (Fig 4D). Taken together, these findings
suggest that IL-28 cytokines act as inhibitors of Th2 and Th17
cell differentiation by favouring Th1 responses in vivo.
IL-28A reprograms lung DCs to promote type 1 responses and
inhibit Th2 cell development in vivo
To understand how IL-28A controls T helper cell differentiation
and Th2-mediated allergic airway disease, and explain the
strong Th1-polarizing capacity of IL-28A in vivo, we assessed
the expression of IL-28Ra on lung immune cells. Using cell
sorting and quantitative PCR, we found that lung CD11cþ DCs
and cultured bone marrow derived DCs expressed high levels
of IL-28Ra mRNA (Fig 5A). Consistently, alveolar macro-
phages and DC-like cells present in the lung parenchyma
stained positive for IL-28Ra protein expression by immuno-
histochemistry (Fig 5B), while peribronchial inflammatory cell
infiltrates were negative. In contrast, sorted CD4þ T cells from
the lung or the spleen, or in vitro differentiated T helper cells
from the spleen, did not express significant levels of IL-28Ra
mRNA (Fig 5A) and IL-28A treatment did not affect their
activation or differentiation to T helper subsets (Supporting
Information Fig S5A–D).
We then asked whether IL-28A treatment could affect lung
CD11cþ DC function. First, we found that IL-28A-treated lung
CD11cþ DCs cultured in the presence of LPS expressed
significantly higher levels of T-bet, a transcription factor
recently described to confer a Th1 polarizing phenotype to
DCs (Lugo-Villarino et al, 2003; Wang et al, 2006), than control
cells (Fig 5C and Supporting Information Fig S4B). This was
disease-relevant as many allergens trigger TLR4 activation
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Figure 4. IL-28 signalling is required for skewing T
helper cell differentiation to a Th1 cytokine profile.
A. Primary Th2 cell responses in OVA/alum immu-
nized IL-28Raþ/þ and IL-28Ra/ mice 6 days
post-immunization. Cytokine levels in super-
natants of OVA-stimulated splenocyte cultures
expressed as mean values SEM of five mice per
group are shown. One representative of two
independent experiments is shown.
B. Primary Th1 cell responses in OVA/alum immu-
nized IL-28Raþ/þ and IL-28Ra/ mice 6 days
post-immunization. Levels of IFN-g in super-
natants of OVA-stimulated splenocyte cultures
expressed as mean values SEM of five mice per
group are shown. One representative of two
independent experiments is shown.
C. IFN-g production from CD4þ and CD8þ T cells of
OVA/alum immunized IL-28Raþ/þ and IL-28Ra/
mice 6 days post-immunization. Levels of IFN-g in
supernatants of OT-II and OT-I-stimulated sple-
nocyte cultures expressed as mean values SEM
of five mice per group are shown. One represen-
tative of two independent experiments is shown.
D. Effect of IL-28A expressing adenovirus (AdIL-28)
treatment on primary Th2 cell responses of OVA/
alum immunized C57BL/6 wild-type mice. AdIL-
28, Ad0 or vehicle control (PBS) were adminis-
tered to mice 1 day pre-immunization and T cell
responses assessed 6 days post-immunization.
Cytokine levels in supernatants of OVA-stimulated
splenocyte cultures expressed as mean
values SEM of five mice per group are shown.
One representative of two independent exper-
iments is shown. p<0.05; p<0.01; ns, non-
significant.
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either because of structural mimicry with LPS or contamination
by LPS itself (Hammad et al, 2009; Trompette et al, 2009).
Second, IL-28A induced the production of significant levels of IL-
12p70, a key cytokine mediating Th1 development, in both lung
CD11cþ DCs and bone marrow DCs cultured with LPS (Fig 5D–
E). This is particularly important as lung CD11cþ DCs are
programmed to induce Th2 polarization and make little IL-12
even in response to LPS stimulation (Dodge et al, 2003). Finally,
IL-28A down-regulated the expression of OX40 ligand (OX40L)
on CD11cþ DCs (Fig 5F and Supporting Information Fig S6A), a
key costimulatory signal for optimal Th2 priming and memory
induction in vivo (Jenkins et al, 2007).
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Figure 5. IL-28A modulates DC function to up-regulate IL-12 and promote Th1 over Th2/Th17 cell development.
A. Real-time PCR analysis of IL-28Ra mRNA levels of purified CD11cþ DCs and CD4þ T cells from the lung or spleen, or in vitro differentiated Th1, Th2 and Treg
cells. Results are expressed as mean levels SEM of IL-28Ra expression relative to GAPDH.
B. Immunohistochemical analysis of IL-28Ra in lung sections from OVA sensitized and challenged mice. IL-28Ra was detected in alveolar macrophages and DC-
like cells (black arrows) and alveolar epithelial cells (blue arrows) whereas inflammatory infiltrates were mostly negative (red arrows). Photomicrographs of
lung sections stained with antibody control (I.C.) or IL-28Ra antibody are shown. Specific staining is depicted in brown; nuclei are stained blue with
hematoxylin.
C. T-bet expression of lung CD11cþ cells from naı̈ve BALB/c mice. Purified lung CD11cþ cells were cultured in the presence or absence of IL-28A for 24 h and T-bet
mRNA levels assessed by real-time PCR. Results are expressed as mean fold induction SEM relative to untreated cells using the 2DDCt method.
D. IL-12 induction from lung CD11cþ cells after IL-28A treatment in vivo. Lung CD11cþ cells isolated from PBS and IL-28A treated naı̈ve C57BL/6 mice were
cultured with LPS (1mg/ml) for 24 h. IL-12p70 levels in cell supernatants are expressed as mean values SEM of four mice per group.
E. IL-12 induction from BM derived CD11cþ cells after IL-28A treatment in vitro. BM DCs were cultured with LPS (1mg/ml) in the presence or absence of IL-28A
(100 ng/ml) for 24 h. IL-12p70 levels in cell supernatants are expressed as mean values SEM and are representative of three independent experiments.
F. FACS analysis of lung CD11cþMHCIIþCD11bþ DCs after IL-28A treatment of CD11cþMHCIIþCD11bþ DCs from whole lung digests of OVA sensitized mice were
analysed for the expression of OX40L. Results are expressed as mean fluorescence intensity (MFI) SEM of five mice per group. Isotype control (I.C.) MFI levels
are also shown.
G. Defective Th2-priming capacity of lung CD11cþMHCIIþCD11bþ DCs after AdIL-28 treatment. Lung CD11cþMHCIIþCD11bþ DCs sorted from AdIL-28 (DC/AdIL-
28), Ad0 (DC/Ad0) or vehicle control treatment (DC/PBS) were cultured with purified CD4þ T cells from OT-II transgenic mice for 7 days and supernatants
assessed by ELISA. Cytokine levels expressed as mean SEM from four mice per group are shown. One representative of two independent experiments is
shown. p<0.05; p< 0.01; p<0.001; ns, non-significant.
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Functionally, IL-28A-mediated modulation of CD11cþ DCs
profoundly affected their ability to induce Th2 and Th17 cell
responses in vivo. Sorted lung CD11cþMHCIIþCD11bþDCs from
AdIL-28-treated mice, a major and critical DC subset for the
development of allergic responses in the lung (Julia et al, 2002;
van Rijt et al, 2005), had an increased capacity to drive Th1 and
a reduced capacity to drive Th2 or Th17 differentiation of OVA-
specific naive CD4þ T cells from OT-II transgenic mice when
compared to lung CD11cþMHCIIþCD11bþDCs fromAd0-treated
or vehicle control mice (Fig 5G). Furthermore, immunization of
naı̈ve mice with IL-28A-treated BM DC pulsed with OVA
profoundly inhibited the generation of Th2 and Th17 responses
while Th1 polarization was enhanced (Supporting Information
Fig S6B–C). Overall, these findings suggest that through the
induction of IL-12, and possibly through the down-regulation of
OX40L, IL-28A reprograms CD11cþ DCs to promote type 1
responses and inhibit Th2 and Th17 cell development and
associated pathology in vivo.
Adoptive transfer of IL-28A-treated CD11cR DCs promotes
immune shifting to a Th1 cytokine profile and suppresses
experimental allergic airway disease
To investigate further the possibility that CD11cþ DCs are
involved in the mode of action of IL-28A treatment in allergic
airway disease, we performed adoptive transfer experiments of
DCs from AdIL-28- or control-treated mice. Accordingly, we
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Figure 6. Adoptive transfer of CD11cþ DCs from IL-28A-treated mice mediates Th1 immune skewing and suppresses allergic airway disease.
A. Experimental protocol used for adoptive transfer of CD11cþ DC. C57BL/6 mice received OVA-pulsed spleen CD11cþ DCs from AdIL-28, Ad0 or vehicle control
(PBS)-treated mice 1 day before OVA challenge.
B. BALF differential counts for eosinophils expressed as mean SEM of 7–9 mice per group pooled from two independent experiments are shown.
C. BALF differential counts for neutrophils expressed as mean SEM of 7–9 mice per group pooled from two independent experiments are shown.
D. BALF differential counts for lymphocytes expressed as mean SEM of 7–9 mice per group pooled from two independent experiments are shown.
E. Histological assessment of lung inflammation after adoptive transfer of CD11cþ DC. Hematoxylin and eosin stained lung sections and histological scoring
expressed as mean values SEM from 6 to 7 mice per group are shown.
F. Histological assessment of mucus secretion after adoptive transfer of CD11cþ DC. PAS stained sections and morphometric analysis expressed as mean
values SEM from 6 to 7 mice per group are shown.
G. AHR measured as metacholine-induced increases of total lung resistance (RL) in mechanically ventilated mice. Data are expressed as mean values of
percentage increase from baseline of the total lung resistance SEM from six mice per group. One representative of two independent experiments is shown.
H. T cell responses in MLNs of OVA sensitized and challenged mice after adoptive transfer of CD11cþ DCs. Cytokine levels are expressed as mean values SEM in
supernatants of OVA-stimulated MLN cultures of 7–9 mice per group from two independent experiments. p< 0.05; p<0.01; p< 0.001; ns, non-
significant.
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purified CD11cþ DCs from vehicle control (PBS/DC), Ad0 (Ad0/
DC) or AdIL-28-treated mice (AdIL-28/DC), pulsed them with
allergen and administered them to mice 1 day before OVA
challenge (Fig 6A). Notably, we found that CD11cþ DCs from
AdIL-28-treated mice, but not Ad0- or PBS-treated mice, potently
transferred the suppression mediated by IL-28A on Th2-mediated
allergic airway disease. AdIL-28/DCs significantly reduced the
severity of allergic airway inflammation (Fig 6B–E), decreased
goblet cell metaplasia in lung tissue (Fig 6F) and prevented the
development of AHR (Fig 6G) compared to Ad0- or PBS-treated
mice. This was associated with up-regulation of IFN-g and
suppression of effector Th2 and Th17 responses in MLNs
(Fig 6H). Similar results were also observed when CD11cþ DCs
from AdIL-28- but not Ad0- and PBS-treated mice were
administered to mice 1 day before OVA sensitization (Supporting
Information Fig S7), revealing an inhibitory effect of AdIL-28/DC
in effective Th2 priming induced by OVA/alum immunization as
well. Therefore,modulation of CD11cþDC function to inhibit Th2
and Th17 responses is a critical step involved in IL-28A-mediated
suppression of allergic airway disease.
IL-28A-mediated suppression is critically dependent on IFN-g
and IL-12
As the above data suggested that IL-28A up-regulates type 1
cytokine responses in the lung through the modulation of DC
function, we next examined whether IFN-g is involved in the
immunosuppressive mode of action of IL-28A in allergic airway
disease. Using IFN-g/ mice, we found that the therapeutic
benefit of recombinant IL-28A administration in the effector
phase of allergic airway disease was completely reversed in the
absence of IFN-g. There was no significant difference in
eosinophil, neutrophil or lymphocyte numbers in the BALF
(Fig 7A–B) and no difference in leukocytic cell infiltration
(Fig 7C) and goblet cell metaplasia (Fig 7D) in the lung of
vehicle-treated and IL-28A-treated knockout mice. Moreover,
AHR induced in response to metacholine challenge was
comparable between IL-28A and vehicle-treated mice
(Fig 7E). In MLN cultures of IFN-g/ mice, IL-28A treatment
had no effect in IL-13 or IL-17 production although it slightly but
significantly reduced IL-10 production (Fig 7F). There was also a
tendency for reduced IL-5 production (Fig 7F), although this was
not significant (p¼ 0.0510).
We further investigated whether IL-12, up-regulated in
response to IL-28A in DCs, could be involved in driving IFN-g
production and associated disease suppression. We found that
administration of a neutralizing antibody directed against the p40
subunit of IL-12, but not its isotype control, completely reversed
IL-28A-mediated suppression of allergic airway disease. Anti-IL-
12p40 treatment restored the numbers of eosinophils and
neutrophils in the BALF (Fig 7G–H), the extent of leukocytic
cell infiltration in the lung (Fig 7I) and themetaplasia of bronchial
epithelial cells to goblet cells in the airways (Fig 7J). Anti-IL-
12p40 treatment also abrogated the induction of IFN-g after IL-
28A treatment and restored the magnitude of OVA-specific Th2
and Th17 responses in MLNs (Fig 7K). These findings identify
IFN-g and IL-12 as critical mediators of IL-28A immunosuppres-
sive function in allergic airway disease.
DISCUSSION
IL-28 family cytokines or l-interferons are the latest addition to
the class II cytokine family (Kotenko et al, 2003; Sheppard et al,
2003). They exhibit potent antiviral and anti-tumour function but
their full spectrum of activities remains poorly characterized. In
the present study, we have uncovered a new role of IL-28
cytokines as key regulators of adaptive immunity and allergic
airway disease. By taking advantage of genetically engineered
mice deficient in IL-28R signalling, IL-28A gene transfer and
recombinant IL-28A administration,we show that IL-28 cytokines
are critical for driving Th1 differentiation in vivo while limiting
Th2 and Th17 responses in the airways. Consistently, IL-28Ra/
mice develop exacerbated allergic airway inflammation asso-
ciated with augmented eosinophilic and neutrophilic cell
infiltration in the lung whereas wild-type mice treated with IL-
28A exhibit markedly reduced Th2 and Th17 responses and Th2/
Th17-mediated allergic airway disease. Although our findings are
based on IL-28Ra/ mice and IL-28A treatment, they are likely
to pertain to all IL-28 cytokines as IL-28A shares 96–97% identity
in amino acid sequence with IL-28B and 81% identity with IL-29,
and as all cytokines signal through a common receptor complex
(Kotenko et al, 2003; Sheppard et al, 2003).
Key to the suppressive action of IL-28A was immune shifting
from a Th2/Th17 to a Th1 cytokine profile and induction of IFN-g.
Accordingly, T cells fromwild-typemice treatedwith recombinant
IL-28A exhibited significantly reduced IL-4, IL-5, IL-13 and IL-17
production and markedly up-regulated IFN-g, whereas T cells
from IL-28Ra/ mice exhibited significantly increased levels of
IL-4, IL-5, IL-13 and IL-17, and augmented IgE production.
Moreover, T cell-derived IFN-gwas essential for IL-28A-mediated
inhibition of Th2 and Th17 responses and allergic airway disease
as demonstrated by the lack of protection in IFN-g/mice. This is
in agreement with the potent inhibitory activity of IFN-g in several
aspects of the allergic response in the lung including Th2 and Th17
cytokine production, eosinophilia, neutrophilia, goblet cell
metaplasia and AHR (Cohn et al, 1999; Durrant et al, 2009).
Notably, IL-28A-mediated Th1 skewing and IL-28A-mediated
suppression of allergic airway disease were both dependent on IL-
12 as neutralization of this cytokine abrogated the induction of
IFN-g and reversed the protective action of IL-28A in the
development of allergic airway inflammation. These findings
demonstrate that the activation of the IL-12-IFN-g axis is a rate-
limiting step involved in the suppressive function of IL-28A.
IL-28A-induced immune shifting to a Th1 cytokine profile
was mediated through the modulation of conventional DC
function rather than direct effects on T cells. In agreement with
previous reports (Ank et al, 2008; Doyle et al, 2006; Witte et al,
2009), but in disagreement with some others (Dai et al, 2009),
we found that neither highly purified CD4þ or CD8þ T cells nor
differentiated Th1 or Th2 cells express significant levels of IL-
28RamRNA, and neither of them responds to IL-28 treatment to
up-regulate known IL-28R target genes (data not shown).
Moreover, neither T cell differentiation induced in vitro in the
absence of DCs nor cytokine production of already differentiated
Th0, Th1 or Th2 cells is affected by IL-28A treatment. In
contrast, both CD11cþ lung and bone marrow derived DCs, as
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Figure 7. IFN-g and IL-12 are required for IL-28A-mediated suppression of allergic airway disease. IFN-g/ and wild-type C57BL/6 mice were subjected to
PBS or OVA sensitization and challenge in the presence of IL-28A (IL-28A) or vehicle control (PBS) treatment as in Fig 2A.
A. BALF differential counts of IFN-g/ mice for eosinophils and neutrophils expressed as mean SEM of six mice per group from two independent experiments
are shown.
B. BALF differential counts of IFN-g/ mice for lymphocytes expressed as mean SEM of six mice per group from two independent experiments are shown.
C. Histological assessment of lung inflammation in OVA sensitized and challenged IFN-g/ mice. Hematoxylin and eosin stained lung sections and histological
scoring expressed as mean values SEM from five mice per group are shown.
D. Histological assessment of mucus secretion in OVA sensitized and challenged IFN-g/ mice. PAS stained sections and morphometric analysis expressed as
mean values SEM from five mice per group are shown.
E. AHR measured as metacholine-induced increases in total lung resistance (RL) in mechanically ventilated IFN-g/ mice. Data are expressed as mean values of
percentage increase from baseline of the total lung resistance SEM of five mice per group. One representative of two independent experiments is shown.
F. T cell responses in MLNs of OVA sensitized and challenged IFN-g/ mice. Cytokine levels in supernatants of OVA-stimulated MLN cultures expressed as mean
values SEM of five mice per group are shown. Data are representative of two independent experiments.
G. BALF differential counts of eosinophils from IL-28A (IL-28A) or vehicle control (PBS) treated OVA challenged wild-type mice in the presence of anti-IL-12p40
(anti-IL-12) or isotype control (Ig) antibody. Results are expressed as mean SEM of six mice per group.
H. BALF differential counts of neutrophils from IL-28A (IL-28A) or vehicle control (PBS) treated OVA challenged wild-type mice in the presence of anti-IL-12p40
(anti-IL-12) or isotype control (Ig) antibody. Results are expressed as mean SEM of six mice per group.
I. Histological assessment of lung inflammation in IL-28A (IL-28A) or vehicle control (PBS) treated OVA challenged wild-type mice in the presence of anti-IL-
12p40 (anti-IL-12) or isotype control (Ig) antibody. Histological scoring of hematoxylin and eosin stained lung sections expressed as mean values SEM from
five mice per group is shown.
J. Histological assessment of mucus secretion in IL-28A (IL-28A) or vehicle control (PBS) treated OVA challenged wild-type mice in the presence of anti-IL-12p40
(anti-IL-12) or isotype control (Ig) antibody. Morphometric analysis of PAS stained sections expressed as mean values SEM from five mice per group are
shown.
K. T cell responses in MLNs of IL-28A (IL-28A) or vehicle control (PBS) treated OVA challenged wild-type mice in the presence of anti-IL-12p40 (anti-IL-12) or
isotype control (Ig) antibody. Cytokine levels expressed as mean values SEM of five mice per group are shown. p<0.05; p<0.01; p< 0.001; ns, non-
significant.
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well as spleen CD11cþDCs (Ank et al, 2008), express high levels
of IL-28Ra and respond to IL-28A treatment to up-regulate
known IL-28 target genes such as OAS1 and ISG15. More
importantly, CD11cþ lung or bone marrow derived DCs respond
to IL-28A treatment to acquire a Th1-promoting phenotype.
They up-regulate IL-12, a dominant Th1 cytokine that directly
inhibits Th2 responses and promotes the production of IFN-g.
They also increase T-bet, an important transcription factor for
promoting a Th1-inducing phenotype in DCs (Lugo-Villarino et
al, 2003; Wang et al, 2006) and down-regulate OX40L, a key
costimulatory molecule required for optimal induction of Th2
responses (Jenkins et al, 2007), although the rate-limiting role of
these effects in IL-28A-mediated suppression is unclear.
Consistent with a critical role of DC modulation in IL-28-
mediated suppression, immunization of naı̈ve mice with IL-28A-
treated DC promoted the induction of Th1 over Th2 or Th17 cell
differentiation in vivo whereas adoptive transfer of CD11cþ cells
from IL-28A-treated mice (Supporting Information Fig S7) to
naı̈vemice prior to OVA/alum immunization suppressed allergen
sensitization and subsequent development of allergic disease.
Moreover, administration of IL-28A or adoptive transfer of
CD11cþ cells from IL-28A-treated mice before inhaled allergen
challenge inhibited effector Th2 cell responses in the lung and
ensuing allergic airway inflammation. This was largely due to
modulation of conventional CD11cþMHCIIþCD11bþ DC func-
tion, a major DC subset in the lung specialized for promoting
primary and effector Th2 responses in the airways (Kool et al,
2008; Medoff et al, 2009; van Rijt et al, 2005). Although other DC
subsets may also be involved in IL-28A-mediated Th1 skewing or
suppression of allergic airway disease, our findings place
modulation of CD11cþMHCIIþCD11bþ conventional DC function
at the centre stage of IL-28A mode of action.
In addition to its role in DC modulation, IL-28A may also
affect the activation state of the respiratory epithelium. IL-28Ra
is expressed in the respiratory epithelium and IL-28A treatment
reduces the expression of epithelium-derived cytokines such as
IL-25 and TSLP involved in driving Th2 responses in the lung
(Supporting Information Fig S8). However, whether this is due
to direct effects on epithelial cells or indirect effects on the Th2
response which activates the respiratory epithelium remains to
be determined.
An important role of IL-28 cytokines in T helper cell
differentiation has been suspected. Transgenic expression of
IL-28A was recently shown to augment the induction of Th1
responses and the severity of ConA-induced liver injury (Siebler
et al, 2007). Moreover, addition of recombinant IL-29 was shown
to inhibit Th2 cytokine production, especially IL-13, in human
cell culture systems involving mitogenic stimulation, mixed-
lymphocyte reaction and T cell differentiation assays (Dai et al,
2009; Jordan et al, 2007; Srinivas et al, 2008). This was associated
with a modest increase in IL-12 production after LPS stimulation
of monocyte-derived DCs and a tendency for increased IFN-g
production (Jordan et al, 2007), although direct inhibitory effects
of IL-29 in GATA-3 expression of CD4þ T cells and Th2
differentiation were also proposed (Dai et al, 2009). More
recently, the possibility that IL-29 affects Th2 responses through
themodulation of pDC function has also been raised (Megjugorac
et al, 2009). Our study now builds up on these earlier
observations. It provides the first in vivo evidence that IL-28A
is critically involved in driving both primary and secondary Th1
responses at the expense of Th2 and Th17 cell differentiation
while it reveals for the first time a role for endogenous IL-28
cytokines in this process. Modulation of conventional DC
function to induce IL-12 and drive Th1 differentiation rather
than the direct regulation of T cell function is central to IL-28A
mediated suppression, raising the possibility that differences in
this aspect between mice and humans may exist.
In summary, our study reveals a key regulatory role of IL-28A
in allergic airway disease and provides new insight into the
function of IL-28 cytokines in adaptive immunity. Our findings
are consistent with a model in which low expression of IL-28
family cytokines during allergic inflammation and/or viral
infection predisposes asthmatic patients for exacerbation of
allergic airway disease both via reduced viral clearance and via
inefficient suppression of Th2 and/or Th17 responses. As asthma
constitutes a major ‘epidemic’ of our times, and as viral
exacerbations of asthma are poorly controlled by current
medication and account for the majority of hospitalizations of
asthmatic patients (Sykes & Johnston, 2008), our findings
advocate the clinical development of IL-28 cytokines for therapy.
MATERIALS AND METHODS
Cytokines, antibodies and recombinant adenoviruses
Cytokines and antibodies were from eBioscience (San Diego, CA),
Peprotech (Rocky Hill, NJ) or BD (PharMingen, Heidelberg, Germany) as
detailed in the Supporting Information Materials and methods section.
LPS was from Sigma. Neutralizing anti-IL-12 p40 antibody (Clone
C17.8) and its isotype control (Clone C1.18.4) were purchased from
Bio-X-Cell (West Lebanon, USA). Recombinant replication-deficient E1/
E3-deleted adenoviral vectors were constructed as described in the
Supporting Information Materials and Methods section.
Allergen sensitization and challenge protocol and
treatment regimens
Wild-type mice, IFN-g/ and IL-28Ra/ mice on a C57BL/6J genetic
background were maintained as previously described (Hausding et al,
2004). IL-28Ra/ knockout mice were described elsewhere (Ank et al,
2008). In some experiments, BALB/cJ mice were also used. Unless
indicated otherwise in Results section, 8–10 week old mice were
sensitized with two intraperitoneal injections on days 0 and 7 of 7.5mg
OVA (Grade V; Sigma) complexed with aluminium hydroxide (alum) as
adjuvant (Sigma, Deisenhofen, Germany). On days 14, 15 and 16, mice
received aerosol challenge with 5% w/v OVA in PBS (OVA/OVA) for 30min
per day. Control mice received intraperitoneal injections and challenges
of PBS alone (PBS/PBS). In some cases, mice were treated with
1mg/mouse recombinant IL-28A concurrently with OVA challenges or
5108 i.u. of an adenovirus expressing IL-28A (AdIL-28) and its mock
control (Ad0) 1 day before allergen challenge as indicated in the
experimental protocol. For adoptive transfer experiments, CD11cþ DCs
from AdIL-28, Ad0 or vehicle control (PBS)-treated mice were
administered to mice 1 day before allergen challenge as detailed in
the Supporting Information Materials and methods section. For IL-12
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p40 neutralization experiments, 300mg/mouse of anti-IL-12p40 anti-
body or its isotype control were administered i.p. just before each
treatment with recombinant IL-28A. One day after the last challenge
mice were examined for AHR, bronchoalveolar lavage performed and
tissues (MLNs, spleen and lung) collected for further analysis.
Airway hyper-responsiveness
Airway hyper-responsiveness was measured in anesthetized mechani-
cally ventilated mice (flexiVent, SciReq, Montreal, Canada) 24 h after
the last aerosol exposure as previously described (Xirakia et al, 2010).
In BALB/c mice, AHR was measured invasively using a body
plethysmograph (Buxco Electronics, Inc., Wilmington, NC) as pre-
viously reported (Hausding et al, 2007).
Differential cell counts, T cell responses and flow cytometric
analysis
Differential cell counts of BALF cells, assessment of T cell responses in
MLNs and lung, flow cytometric analysis, sorting and functional
analysis of lung CD11cþ DCs were all performed as described in the
Supporting Information Materials and methods section.
Histology and immunohistochemistry
Histopathologic analysis of inflammatory cells in H&E stained lung
sections, morphometric analysis of PAS stained sections and
immunohistochemistry were performed as described in the Support-
ing Information Materials and methods section.
Primary T cell responses and BM DC studies
Analysis of primary T cell responses and BM DC function were
performed as described in the Supporting Information Materials and
methods section.
Real time–PCR and ELISA
Real-time qRT-PCR and ELISA were performed as described in the
Supporting Information Materials and methods section. For the
analysis of IL-28 levels, BALF was concentrated 10X using Amicon
Ultra-15 centrifugal filter columns (Millipore, USA) with a molecular
weight cut-off of 10 kDa according to the manufacturer’s instructions.
Statistical analysis
Differences were evaluated for significance (p<0.05) by the Student’s
two-tailed t-test for parametric data and the Mann–Whitney U test
for non-parametric data (Excel, PC). Data are given as mean
values SEM.
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The paper explained
PROBLEM:
IL-28 cytokines or type III interferons exhibit potent antiviral and
anticancer function. However, their full spectrum of activities in
the immune system and their role in the context of an
inflammatory disease remain poorly understood. This is despite
recent evidence linking low levels of IL-28 cytokines with the
severity of inflammation in asthma and viral exacerbations of
asthma.
RESULTS:
Using IL-28Ra/mice, IL-28A gene transfer, recombinant IL-28A
administration and an established model of experimental
asthma in mice, we reveal a key function of IL-28 cytokines in
inducing type 1 immunity and protecting from allergic airway
disease. Abrogation of endogenous IL-28 function in IL-28Ra/
mice augmented Th2 and Th17 responses as well as IgE levels
and exacerbated allergic airway inflammation. In contrast, IL-
28A treatment promoted Th1 responses, suppressed Th2 and
Th17 responses and ameliorated allergic airway disease. This was
due to IL-28A-mediated modulation of conventional DC function
inducing IL-12p70 production and Th1 differentiation.
IMPACT:
This work extends our current knowledge on the mechanisms
regulating allergic responses in the airways, provides new insight
about the role of IL-28 cytokines in adaptive immunity and
strengthens the rationale for the therapeutic administration of
IL-28A in allergic asthma and related allergic diseases in humans.
www.embomolmed.org EMBO Mol Med 3, 348–361  2011 EMBO Molecular Medicine 359
of ZymoGenetics that owns intellectual property on IL-28 and
therefore declare conflict of interest. The rest of the authors
have no competing commercial interests in relation to the
submitted work.
For more information
For general information about allergic asthma and allergic diseases:
European Academy of Allergy and Clinical Immunology (EAACI)
http://www.eaaci.net/
European Federation of Allergy and Airways Diseases Patients
Associations (EFA)
http://www.efanet.org/
For related EU-funded research on allergy and asthma:
Global Allergy and Asthma European Network (GA2LEN)
http://www.ga2len.net/
Post-infectious immune reprogramming and its association with
persistence and chronicity of respiratory allergic diseases
http://www.predicta.eu/
Webpage of the working group of E. Andreakos:
http://www.immunology-brfaa.gr/ and http://www.bioacademy.gr/
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